These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19884029)

  • 1. [Quality of storage of thermolabile drugs in patients' homes].
    Cuéllar MJ; Marco JL; Pérez-Castelló I; Castelló Escrivá A
    Rev Calid Asist; 2010; 25(2):64-9. PubMed ID: 19884029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Home storage of biological medications administered to patients with rheumatic diseases.
    Santin G; da Silva MMM; Villarreal VA; Laste LDD; de Freitas Montin E; Betiol LER; Azevedo VF
    Adv Rheumatol; 2020 May; 60(1):30. PubMed ID: 32460880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Utility of Continuous Temperature Monitoring of Refrigerators in a Long-Term Care Facility.
    Worz C; Postolski J; Williams K
    Consult Pharm; 2017 Apr; 32(4):222-227. PubMed ID: 28376987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab.
    van Lümig PP; Driessen RJ; Roelofs-Thijssen MA; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2011 Aug; 165(2):375-82. PubMed ID: 21428975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Karlsson JA; Englund M; Petersson IF; Saxne T; Geborek P
    Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1362-9. PubMed ID: 20506310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine storage in the community: a study in central Italy.
    Grasso M; Ripabelli G; Sammarco ML; Manfredi Selvaggi TM; Quaranta A
    Bull World Health Organ; 1999; 77(4):352-5. PubMed ID: 10327715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving vaccination cold chain in the general practice setting.
    Page SL; Earnest A; Birden H; Deaker R; Clark C
    Aust Fam Physician; 2008 Oct; 37(10):892-6. PubMed ID: 19002316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thermolabile drugs stability faced with an accidental interruption in the cold chain].
    Ricote-Lobera I; Ortiz-Martín B; Fraile-Gil S; Santos-Mena B; Hidalgo-Correas FJ; García-Díaz B
    Farm Hosp; 2014 May; 38(3):169-92. PubMed ID: 24951902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine storage and handling. Knowledge and practice in primary care physicians' offices.
    Yuan L; Daniels S; Naus M; Brcic B
    Can Fam Physician; 1995 Jul; 41():1169-76. PubMed ID: 7647622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis.
    Chilton F; Collett RA
    Musculoskeletal Care; 2008 Mar; 6(1):1-14. PubMed ID: 17726671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.